Evaluation of GLP-2 receptor expression in gastrointestinal neuroendocrine tumors

SUMMARYEVALUATION OF GLP-2 RECEPTOR EXPRESSION IN GASTROINTESTINAL NEUROENDOCRINE TUMORSDr. Şule Namlı sulenamli@yahoo.comDokuz Eylül University Faculty of Medicine Department of GastroenterologyDokuz Eylül University Hospital Department of Gastroenterology İnciraltı / İZMİR 35340Background and aimThe objective is to contribute to developmental pathogenesis of gastrointestinal neuroendocrine tumor(GEP-NET) by presenting the relation between GEP-NET and Glukagon Like Peptid-2 (GLP-2) & GLP-2 R..Material and MethodsThe patients, who were pathologically diagnosed with GEP-NET, among the group of patients, whose tissue samples was collected between 2006-2009 were included in the study. There were 47 patients( 27 F, 20 M, avarage age:54±15.5) in this study. There were also 46 control group patients(25 F,21 M, avarage age: 57.5±14.8). Pathological tissue blocks prepared on poly-L-lysine microscope slides were stained by GLP-2 Receptor Antibody (1:100-1:200, 1 mg/ml) immunohistochemical stainResultsGLP-2R positivity of colon neuroendocrine tumor(NET) group was 30 % (4/13)) and of colon control group was %100. GLP-2R positivity of pancreas NET group was 25% (3/12) while it was 100 % in pancreas control group. The comparison of colon NET and control group showed significant difference(p:0.003). The comparison of pancreas NET and ıts control group also showed statistically significant difference (p<0.001). The comparison of gastric NET and ıts control group didn?t show significant difference(p:0.22)ConclusionNeuroendocrine tumors (NETs) consist of a heterogeneous group of malignancies with slow growth rates and they are rare tumors. Although there is a hypothesis that carcinoid tumors arising from intestinal endocrine cells might also exhibit GLP-2R immunopositivity, and ıt can be used in diagnosis and treatment of these tumors; this study didn?t show an obvious GLP2 R expression in GEP-NET?s. We concluded that GLP2R can notbe as useful as somatostatin reseptors in diagnosis and treatment of these tumors. More studies are needed on this subject with more facts and different methods.Key words: GLP-2R, Gastrointestinal neuroendocrine tumors(GEP-NET))